ClinicalTrials.gg
Enrolling by invitationNCT07075614PTPUpdated May 1, 2026

The Effectiveness of a Parent Training Program for Children With Autism Spectrum Disorder and High-Risk Infants: A Case-Control Study

An interventional study of Parent Training Program and routine care in Autism Disorder, sponsored by Umraniye Education and Research Hospital. Enrolling by invitation at 1 site in Turkey (Türkiye). Open to participants aged 0 Months to 5 Years. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Umraniye Education and Research Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Jul 2024, registered Jul 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
0 Months to 5 Years
Sex
All
01

Study summary

The aim of this study is to evaluate the effectiveness of a parent training program on the severity of autism-related symptoms in two groups: (1) infants under the age of 2 who show early signs of autism, and (2) children aged 2 to 5 years who have been diagnosed with Autism Spectrum Disorder (ASD). The study also aims to assess the program's impact on the quality of life and stress levels of the children's parents or caregivers.

The study will include children aged 0 to 5 years who are either considered at risk for autism or have an ASD diagnosis, along with their caregivers. A total of 250 participants are expected to enroll in the study. Informed consent will be obtained from all parents or caregivers before participation.

After consent, the 250 children will be randomly assigned to one of two groups:

Group A: Parent Training Program + Routine Care Group B: Routine Care Only While Group B will receive standard treatments such as education and psychotherapy and a single psychoeducational session about autism and its treatment, Group A will receive the same routine care plus the structured Parent Training Program.

Children in both groups will be assessed before the intervention begins and again after 12 weeks. Evaluations will be conducted with the support of professionals using standardized tools. Caregivers will complete a background information form with the help of the research team.

To assess symptom severity, the Modified Checklist for Autism in Toddlers (M-CHAT), the Childhood Autism Rating Scale (CARS), and the Clinical Global Impression Scale (CGI) will be administered by clinicians. General developmental levels will be evaluated using screening tools such as the Denver Developmental Screening Test or AGTE. Caregivers will also complete the Quality of Life in Autism-Parent Version and the Parenting Stress Index.

02

Conditions studied

  • Autism Disorder

Browse trials for

Keywords

  • autism
  • parent training program
03

In context

Autistic Disorder

1,030 studies on the registry are indexed under Autistic Disorder; 266 are open to participants now.

This study's planned enrollment of 250 is above the median of 49 across 811 interventional studies indexed under Autistic Disorder.

Browse Autistic Disorder studies →

Lead sponsor

Umraniye Education and Research Hospital is the lead sponsor of 61 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Months to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Having a child over the age of 2 diagnosed with Autism Spectrum Disorder (ASD), or having a high-risk infant under the age of 2 showing signs of autism
  • Willingness to participate in the study
  • Parent/caregiver must have completed at least primary school education

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate in the study
  • The child has a sensory, physical, or neurological disorder
  • The parent or primary caregiver has a diagnosed psychiatric disorder that significantly impairs functioning
  • The parent or caregiver has any physical illness that affects their interaction with the child (e.g., physical disability, visual or auditorial impairment)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
250 participants (estimated)

Study arms

  • Active comparator
    Intervention Group

    Parent Training Program + Routine Care

    Behavioral: Parent Training Program

  • Other
    Control Group

    routine care

    Other: routine care

Interventions

  • BehavioralParent Training Program

    Parent Training Programs are complementary interventions to special education, implemented by parents to support the social, cognitive, and behavioral development of children with autism and other developmental disorders. Throughout the program, key developmental skills that children are expected to acquire-such as social skills (eye contact, joint attention, play, imitation), language, cognitive, motor, and self-care abilities-are explained using sample photos and simple instructions. Additionally, the program provides guidance on how to foster secure attachment between parent and child and how to support social-communicative skills through warm, responsive interactions in daily life.

    Also known as: Routine Care

  • Otherroutine care

    Standard care routinely provided to participants within clinical services

    Also known as: Control Group

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Autism Severity as Measured by the Childhood Autism Rating Scale (CARS)

    Autism severity will be assessed using the Childhood Autism Rating Scale (CARS), a clinician-rated tool that evaluates behavior in 15 areas related to communication, social interaction, and sensory responses. Each item is rated on a scale from 1 (no signs of autism) to 4 (severe symptoms), with a total score ranging from 15 to 60. The total CARS score will be recorded at baseline (prior to intervention) and again. The primary outcome is the change in total score, which reflects improvement or worsening in the severity of autism symptoms over time.

    Time frame: Baseline, After 1 and 3 Months from Intervention

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Jan 2026, 18 months.

Of 354 non-industry interventional studies with no phase under Autistic Disorder, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 52. This study's 18 months is below that.

Counting every sponsor, half of 366 studies reached it within 26 months; a quarter within 13 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2025
First posted
Jul 20, 2025
StartActual
Jul 10, 2024
Primary completionActual
Jan 31, 2026
CompletionEst.
May 2026
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07075614
Lead sponsor
Umraniye Education and Research Hospital
Collaborators
Other organizations
Responsible party
Prof. Dr. Canan Tanıdır (Prof Dr, Istanbul Gelisim University) — Principal investigator
First posted
Jul 20, 2025
Start date
Jul 10, 2024
Primary completion
Jan 31, 2026
Completion
May 2026 (estimated)
Last update
May 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion